Mancini Anthony 4

What Happened

• Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised 37,450 stock options on March 25, 2026 by paying $33.62 per share (total exercise cost $1,259,069) and sold 37,450 shares the same day in multiple open‑market trades for aggregate proceeds of about $3,578,820. The Form 4 shows a related derivative line reported at $0 (conversion/settlement).

Key Details

• Transaction date: 2026-03-25; Form filed: 2026-03-26 (timely).
• Exercise: 37,450 shares @ $33.62 each — $1,259,069 paid.
• Sales: total 37,450 shares sold across multiple trades at weighted avg prices (breakdowns reported with ranges: $92.69–$97.34 depending on tranche); aggregate proceeds ≈ $3,578,820.
  • 1,800 @ $93.22 (weighted avg for that block)
  • 3,128 @ $94.16
  • 21,086 @ $95.49
  • 11,036 @ $96.43
  • 400 @ $97.21
• Footnotes: trades executed under a 10b5-1 trading plan adopted Dec 24, 2025 (F1). Multiple-trade ranges and weighted-average prices are disclosed (F3–F7). Form notes holdings include 54,400 Restricted Stock Units (F2).
• Shares owned after transaction: the exercised shares were sold the same day (no net increase from this exercise); total reported holdings after the transaction are not fully specified in the excerpt beyond the 54,400 RSUs reference.

Context

• This is an exercise-and-sale (option exercise followed by immediate open‑market sales), commonly executed to realize gains or cover exercise costs/taxes; the 10b5‑1 plan indicates the sales were pre‑planned and automated. The derivative line at $0 reflects conversion/settlement reporting conventions for exercised options. The filing appears timely (reported the next day).